-
公开(公告)号：EP3960169A1
公开(公告)日：2022-03-02
申请号：EP21188327.7
申请日：2018-06-13
申请人： EURO-CELTIQUE S.A.
IPC分类号： A61K31/4184 , A61K31/282 , A61K31/337 , A61K41/00 , A61K45/06 , A61P35/00
摘要： There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of ovarian cancer in a patient in need thereof.
-
公开(公告)号：EP2758052B9
公开(公告)日：2019-03-27
申请号：EP12831417.6
申请日：2012-09-14
申请人： EURO-CELTIQUE S.A.
发明人： CHEN, Yu , YANG, Lan , FENG, Feiyu , GE, Qiufu , GUO, Dianwu , CHEN, Yi
IPC分类号： A61K47/50 , A61K47/40 , A61K31/4184 , A61K31/4164 , A61K31/16 , A61P35/00 , A61K9/19 , A61K9/00 , C07D235/16
-
公开(公告)号：EP3328431A1
公开(公告)日：2018-06-06
申请号：EP16747572.2
申请日：2016-07-28
申请人： Euro-Celtique S.A.
CPC分类号： A61K9/7061 , A61K9/0014 , A61K31/485 , A61K47/10 , A61K47/12 , A61P25/04
摘要： The present invention provides a transdermal delivery system comprising (R)-dihydroetorphine, or a salt, hydrate or derivative thereof, wherein said system has a rapid onset of (R)-dihydroetorphine plasma concentration characterised by the mean in vivo plasma concentration of (R)-dihydroetorphine achieving at least 50% of its Cmax in less than 20 hours, preferably in less than 18 hours and more preferably in less than 12 hours, after application of the system to the skin of a human subject, e.g. when based on the mean plasma concentration versus time curve.
-
4.发明授权Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone 有权制备含有少于25ppm 14-羟可待因酮的盐酸羟可待酮的方法
公开(公告)号：EP2316837B1
公开(公告)日：2018-01-10
申请号：EP10011788.6
申请日：2005-03-30
申请人： EURO-CELTIQUE S.A.
发明人： Chapman, Robert , Rider, Lonn S. , Hong, Qi , Kyle, Donald , Kupper, Robert
IPC分类号： C07D489/08 , A61K31/485 , A61P29/00
CPC分类号： C07D489/08 , A61K9/14 , A61K9/20 , A61K9/2095 , A61K9/48 , A61K9/4833 , A61K31/485 , C07D489/02 , C07D489/04
摘要： In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
-
公开(公告)号：EP3150228A3
公开(公告)日：2017-06-28
申请号：EP15181540.4
申请日：2004-04-19
申请人： EURO-CELTIQUE S.A.
CPC分类号： A61K9/2081 , A61K9/1617 , A61K9/1635 , A61K9/282 , A61K9/2826 , A61K9/2846 , A61K9/2866 , A61K9/4808 , A61K9/4858 , A61K9/4866 , A61K9/5026 , A61K9/5047 , A61K9/5073 , A61K9/5084 , A61K9/5123 , A61K9/5138 , A61K31/485 , A61K45/06 , A61K2300/00
摘要： Disclosed in certain embodiments is a dosage form comprising a plurality of extruded particles comprising an adverse agent or antagonist and a layer disposed about the particles.
摘要翻译： 在某些实施方案中公开了包含多个挤出颗粒的剂型，所述挤出颗粒包含不利剂或拮抗剂和围绕所述颗粒设置的层。
-
公开(公告)号：EP2425824B1
公开(公告)日：2017-05-10
申请号：EP11177516.9
申请日：2003-04-04
申请人： EURO-CELTIQUE S.A.
IPC分类号： A61K9/20 , A61K9/16 , A61K31/485
CPC分类号： A61K31/485 , A61K9/0053 , A61K9/1617 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/70 , Y10S514/81 , Y10S514/812
摘要： The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
摘要翻译： 本发明涉及储存稳定的药物制剂，其包含优选两种活性化合物在不可膨胀的扩散基质中，由此化合物以持续的，不变的形式从基质中释放，如果存在几种化合物，则以独立的方式释放基质， 相对于乙基纤维素和至少一种脂肪醇的实质释放特性。 本发明还涉及生产这种药物制剂的方法。
-
公开(公告)号：EP3150228A2
公开(公告)日：2017-04-05
申请号：EP15181540.4
申请日：2004-04-19
申请人： EURO-CELTIQUE S.A.
CPC分类号： A61K9/2081 , A61K9/1617 , A61K9/1635 , A61K9/282 , A61K9/2826 , A61K9/2846 , A61K9/2866 , A61K9/4808 , A61K9/4858 , A61K9/4866 , A61K9/5026 , A61K9/5047 , A61K9/5073 , A61K9/5084 , A61K9/5123 , A61K9/5138 , A61K31/485 , A61K45/06 , A61K2300/00
摘要： Disclosed in certain embodiments is a dosage form comprising a plurality of extruded particles comprising an adverse agent or antagonist and a layer disposed about the particles.
摘要翻译： 在某些实施方案中公开的是包含多个包含不利剂或拮抗剂的挤出颗粒和围绕颗粒设置的层的剂型。
-
公开(公告)号：EP2648699B1
公开(公告)日：2017-03-01
申请号：EP11808286.6
申请日：2011-12-09
申请人： Euro-Celtique S.A.
发明人： MOHAMMAD, Hassan
CPC分类号： A61J3/00 , A61K9/00 , A61K9/1635 , A61K9/1652 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/5084 , A61K31/00 , A61K31/485 , B29B9/12
-
公开(公告)号：EP2289492B1
公开(公告)日：2016-12-07
申请号：EP10010921.4
申请日：2003-03-14
申请人： EURO-CELTIQUE S.A.
IPC分类号： A61K9/20 , A61K9/24 , A61K9/16 , A61K9/50 , A61K31/485 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/22 , A61K47/14
CPC分类号： A61K9/1617 , A61K9/1676 , A61K9/2009 , A61K9/2054 , A61K9/2077 , A61K9/4858 , A61K9/5078 , A61K31/485
摘要： The present invention relates to compositions and methods of stabilizing naltrexone hydrochloride.
-
公开(公告)号：EP2351555B1
公开(公告)日：2016-10-05
申请号：EP10010922.2
申请日：2005-02-15
申请人： EURO-CELTIQUE S.A.
发明人： Reidenberg, Bruce , Shevchuk, Ihor , Tavares, Lino , Long, Kevin , Maskiewicz, Richard , Shameem, Mohammed
IPC分类号： A61K9/16 , A61K9/70 , A61K31/485 , B09B3/00
CPC分类号： A61K31/485 , A61K9/0014 , A61K9/1611 , A61K9/1647 , A61K9/703 , A61K9/7061 , A61K9/7092 , B09B3/0075 , B09B2220/14
摘要： The present invention provides abuse-resistant transdermal delivery devices containing an opioid agonist intended for analgesic purposes in pain patients.
-
-
-
-
-
-
-
-
-
搜索结果
709 条记录 (耗时 0.032 秒)
